Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426496 | 0.87 | GRM5 (0.44) | GRM5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL13660373 | 0.83 | MAPT (0.32) | SMN1; SMN2NPC1RAB9AMAPTLMNA | |
| SCHEMBL22787173 | 0.82 | BRD4 (0.51) | GRM5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL22773520 | 0.82 | LTB4R (0.42) | GRM5SMN1; SMN2LTB4RLTB4R2 | |
| SCHEMBL8720173 | 0.80 | NR5A1 (0.39) | NPC1RAB9ACYP3A4 | |
| SCHEMBL8720471 | 0.79 | NR5A1 (0.41) | NPC1RAB9ACYP3A4TSHR | |
| SCHEMBL8722593 | 0.79 | NR5A1 (0.41) | NPC1RAB9ACYP3A4TSHR | |
| SCHEMBL8720480 | 0.79 | NR5A1 (0.41) | NPC1RAB9ACYP3A4TSHR | |
| SCHEMBL8720107 | 0.79 | NR5A1 (0.41) | NPC1RAB9ACYP3A4TSHR | |
| SCHEMBL14149269 | 0.79 | MEN1 (0.32) | NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605265-B2 | Heterodimers and methods of using them | Biotechnology Research Corporation Ltd. (CN) | 2009-10-20 | — | — | US | disclosed |
| WO-2008091901-A1 | HETERODIMERS AND METHODS OF USING THEM | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2008-07-31 | — | — | WO | disclosed |
| US-20080176308-A1 | Heterodimers and Methods of Using Them | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176308-A1 | Heterodimers and Methods of Using Them | GRIN2A, GRIN3A, GRIN1 | GRM5 22/4885SMN1; SMN2 1617/4885NPC1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.